Lumira Ventures partners with exceptional entrepreneurs to build life science companies that transform the lives of patients worldwide.
Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting.
August 15, 2023
Montreal, Quebec – August 15, 2023 – Thryv Therapeutics Inc., a clinical stage biotechnology company developing therapies for rare diseases including Congenital Long QT Syndrome... Learn More
Cadence Neuroscience Secures $26 Million in Series B Financing for Clinical Trials of Epilepsy Neuromodulation Therapy
May 23, 2023
Cadence Neuroscience announced that it has secured $26 million in Series B financing. The round was led by Angelini Lumira Biosciences Fund (co-managed by Lumira Ventures and Angelini Ventures)... Learn More
Antiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEO
April 27, 2023
Proceeds to Support Key Efficacy Studies for ABI-2280 including Phase 2 Trial in High-Grade Cervical Intraepithelial Neoplasia (CIN 2,3) and Exploratory Study as Treatment for High-Risk HPV... Learn More
Cyrano Therapeutics Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of CYR-064 to Treat Post-Viral Smell Loss (Hyposmia)
January 18, 2023
Currently no FDA-approved therapy for this serious condition Initiation of Phase 2 clinical trial expected to occur in Q2 2023 Cyrano Therapeutics, a biopharmaceutical company developing... Learn More
Our investment team of 12 professionals has over 225 years of collective experience founding, managing and investing in healthcare and life sciences companies. We value collaboration, creativity and challenging conventional wisdom.
Lumira donates a portion of partner time and profits to support the research, translational medicine and healthcare access missions of over a dozen leading healthcare foundations.
"Lumira's philanthropic vision of leveraging research, resources and knowledge to improve the lives of patients will strengthen St. Michael's ability to accelerate the pace."
Dr. Arthur Slutsky | Vice-President
Vice-President of Research at St. Michael's Hospital
"Lumira's model provides a new pathway for philanthropy to partner with investors in advancing healthcare innovation."
Barbara Grantham | President & Ceo
VGH & UBC Hospital Foundation
“This distinctive approach to supporting innovation is very creative, very much needed and very much appreciated by Princess Margaret and University Health Network.”
Paul Alofs | President & Ceo
Princess Margaret Cancer Foundation
Our team is strategically situated across North America to identify innovative companies within and outside the traditional start-up hubs, and help them access capital, talent and strategic partners.
141 Adelaide Street
Canada, M5H 3L5
3, Place Ville Marie
Bureau 12350, Niveau L
Canada, H3B 0E7
1021 West Hastings Street,
Canada, V6E 0C3
303 Wyman Street